<DOC>
	<DOCNO>NCT02145026</DOCNO>
	<brief_summary>This phase IV , prospective , multi-center , open-label study ass effectiveness safety profile epoetin beta ( RecormonÂ® ) treatment symptomatic anemia adult participant associate low/intermediate-1-risk MDS . After screen , eligible participant treat epoetin beta recommend approved label international guideline use epoetin MDS participant dosage adjust basis erythroid response .</brief_summary>
	<brief_title>A Study Epoetin Beta Treatment Anemic Participants With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult participant low intermediate1 risk MDS No previous treatment hematopoietic growth factor within 3 month prior screen Symptomatic anemia ( hemoglobin &lt; 10 g/dL ) determine investigator Serum erythropoietin &lt; 500 milliunits/milliliter ( mU/mL ) within 14 day prior first dose study treatment Require red blood cell transfusion dependent &lt; 4 unit within 8 week prior screen Clinically stable least 1 month prior entry study For female participant childbearing potential male participant partner childbearing potential , agreement ( participant and/or partner ) use highly effective form ( ) contraception Contraindications know hypersensitivity active substance and/or excipients epoetin beta treatment Poorly control hypertension assess investigator History Acute Myeloid Leukemia ( AML ) high risk AML Administration another investigational drug within 1 month screening plan study period Previously document evidence Pure Red Cell Aplasia ( PRCA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>